CDK4 and breast carcinoma: In the past decades, a great amount of effort has been directed toward developing inhibitors of CDK, resulting in the success of CDK4/6 inhibitors (palbociclib [55], ribociclib [56], and abemaciclib [57]) for the treatment of advanced breast cancer.